Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Want to cut your energy bills? Here’s how five experts are doing it 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
WALTHAM, Mass., March 15, 2016 -- Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Thursday, March 17, 2016, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s fourth quarter and year-end 2015 financial results.
| Thursday March 17th, 8:30 a.m. (ET) | ||||
| Dial in (domestic): | 877-324-1976 | |||
| Dial in (international): | 631-291-4550 | |||
| Conference ID: | 62665317 | |||
A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com. The webcast will be archived following the call at www.ilgenetics.com.
About Interleukin Genetics.
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals and their healthcare providers to manage existing health and wellness through genetics-based insights and actionable guidance. Interleukin Genetics leverages its research, intellectual property, and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict genetic test for periodontal disease and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvements Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Investor Contacts: Hans Vitzthum LifeSci Advisors, LLC. (212) 915-2568 [email protected]
